10-Q: PharmaCyte Biotech Reports Q1 Loss Amid Clinical Hold & Strategic Review

PharmaCyte Biotech reported a significant net loss in Q1 2026, driven by fair value adjustments, as it continues to address an FDA clinical hold and re-evaluate its core programs.

Summary

• Reported a net loss of $8.36 million for the three months ended July 31, 2025, a significant decline from a $23.42 million net income in the prior year period.
• Cash and cash equivalents decreased to $13.18 million as of July 31, 2025, from $15.17 million at April 30, 2025.
• Operating expenses decreased by 33% to $848,305, primarily due to a 36% reduction in general and administrative expenses.
• The company continues to address an FDA clinical hold on its Investigational New Drug (IND) application for a pancreatic cancer clinical trial, having completed several requested preclinical studies.
• A Business Review Committee and Strategic Scientific Committee are evaluating the company's business, strategy, and relationship with SG Austria, leading to curtailed spending on development programs.
• Subsequent to the quarter, PharmaCyte raised $7 million through a private placement of Series C convertible preferred stock and warrants.
• Also, subsequent to the quarter, the company agreed to invest $3 million in TNF Pharmaceuticals, Inc. for Series H convertible preferred stock and warrants.
• Settled a breach of contract lawsuit with H.C. Wainwright & Co., LLC for $1.55 million and issued warrants.

Sentiment

Score: 3

Explanation: The company reported a substantial net loss driven by fair value adjustments and continues to face an FDA clinical hold on its primary drug candidate, coupled with internal control weaknesses and a strategic review that has curtailed spending. While some progress has been made on FDA requests and a capital raise was completed post-quarter, the overall financial performance and operational uncertainties present a negative outlook.

Positives

• Operating loss decreased to $848,305 for the three months ended July 31, 2025, from $1,268,887 in the prior year, indicating improved operational efficiency.
• General and administrative expenses decreased by $419,723, or 36%, primarily due to reduced compensation expenses, investor relations fees, and legal/professional fees.
• Successfully completed several FDA-requested preclinical studies, including product stability, Master Cell Bank (MCB) cell stability, P450 2B1 gene sequencing, biocompatibility, and systemic toxicity testing.
• Secured $7 million in gross proceeds from a private placement of Series C convertible preferred stock and warrants in August 2025, enhancing liquidity.
• Resolved a breach of contract legal proceeding with H.C. Wainwright & Co., LLC for $1.55 million, removing a contingent liability.

Negatives

• Reported a net loss of $8,360,096 for the three months ended July 31, 2025, a significant reversal from a net income of $23,421,355 in the same period last year, largely due to fair value adjustments of investments and warrants.
• Cash and cash equivalents decreased by approximately $2 million during the quarter, from $15,172,163 to $13,178,305.
• Experienced a significant loss of $2,839,000 from the change in fair value of the investment in TNF Pharmaceuticals, Inc. Series G Preferred Stock.
• Incurred a substantial loss of $4,832,000 from the change in fair value of TNF Series G Warrants.
• Cash used in operating activities increased to $1,993,981 for the three months ended July 31, 2025, compared to $373,297 in the prior year, mainly due to a $1.3 million legal settlement payment.
• The FDA clinical hold on the Investigational New Drug (IND) application for the pancreatic cancer clinical trial remains in effect, delaying development.
• The Board has curtailed spending on development programs pending a strategic review, which may cause further delays.
• Identified material weaknesses in internal control over financial reporting related to insufficient segregation of duties of the Chief Financial Officer and insufficient management review controls.

Risks

• The FDA clinical hold on the Investigational New Drug (IND) application for the planned clinical trial in Locally Advanced, Inoperable Pancreatic Cancer (LAPC) continues, requiring additional preclinical studies and information.
• The company's relationship with SG Austria is under review due to expired licensed patents, the sole residence of know-how with SG Austria, and potential misalignment of incentives, which could lead to reevaluation or termination of programs dependent on SG Austria.
• Curtailment of spending on development programs pending the Business Review Committee and Board's review may cause additional delays in addressing the FDA clinical hold and overall development timelines.
• The company expects to need additional capital to complete a clinical trial for pancreatic cancer, and future equity financing could be significantly dilutive, while debt financing may involve restrictive covenants.
• Inability to access capital on a timely basis would have a material adverse effect on the business, financial condition, and results of operations.
• Operating in an industry subject to rapid technological change, competition, and government regulation poses significant risks, including those related to clinical testing, regulatory approval, material supply, manufacturing, and capital raising.
• Material weaknesses in internal control over financial reporting, specifically insufficient segregation of duties of the Chief Financial Officer and insufficient management review controls, could adversely affect the ability to record, process, summarize, and report financial information.

Future Outlook

The company expects its current cash and cash equivalents of approximately $15.7 million (as of the filing date) to be sufficient for at least the next twelve months. However, additional capital will be needed to complete a clinical trial for pancreatic cancer, which may involve dilutive equity financing or restrictive debt. The company is actively working to resolve the FDA clinical hold on its LAPC IND and is in ongoing dialogue with SG Austria to prepare for next steps, while also identifying alternative approaches to expand its prodrug/activator technology for cancer treatment.

Management Comments

• We believe that the technology upon which the LAPC treatment will be based, intra-arterial chemotherapy, has been used in five clinical trials in humans. Our position is that the data available from these human clinical trials supersedes large animal study data.
• We are waiting for the FDAs responses and hope the FDA will accept that the LAPC treatment now meets manufacturing standard requirements, which have significantly improved since the clinical hold was first placed.
• We believe that the prodrug/activator technology is well suited to address the shift from cure/enhanced survival to creating a zone of clearance around blood vessels adjacent to tumor. This zone of clearance improves the probability of successful surgical resection of LAPC, which has been shown to improve survival.
• We are actively working to ensure strong ties and interactions to minimize the inherent risks regarding success.
• We do not believe there are factors which will cause materially different amounts to be reported than those presented in this Report. We aim to assess this regularly to provide accurate information to our shareholders.

Industry Context

PharmaCyte Biotech operates in the highly competitive and regulated biotechnology sector, specifically focusing on cellular therapies for cancer. The ongoing FDA clinical hold on its pancreatic cancer treatment highlights the significant regulatory hurdles and lengthy development timelines inherent in drug development. The company's strategic review and efforts to secure additional capital are common challenges for early-stage biotechs, especially those without revenue-generating products. The reliance on a third-party (SG Austria) for core technology and know-how, coupled with expired patents, presents a unique risk that could impact its competitive positioning and intellectual property strategy within the industry.

Corporate Governance

Legal Proceedings

• Settled a breach of contract complaint with H.C. Wainwright & Co., LLC, filed on December 4, 2023, for $1.55 million and the issuance of warrants to purchase 656,250 shares of common stock.

Related Party Transactions

• The company owns 13.9% equity in SG Austria, from which it acquired licenses for Cell-in-a-Box technology. The investment in SG Austria was fully impaired as of April 30, 2024.
• The company's Chief Executive Officer serves on the board of directors of Femasys Inc., in which PharmaCyte has an investment.
• The company's Chief Executive Officer serves on the board of directors of TNF Pharmaceuticals, Inc., in which PharmaCyte has an investment.
• The company has service agreements with SG Austria and its subsidiaries for IND-related work, with an estimated remaining cost of approximately $157,000 for the related party portion.

Stakeholder Impact

• Shareholders: Experienced a significant net loss and diluted earnings per share, along with potential future dilution from the recent Series C preferred stock and warrant issuance. The ongoing clinical hold and strategic review create uncertainty regarding the company's core value proposition.
• Employees: Spending on development programs has been curtailed, which could impact job security or project involvement, although stock-based compensation was still recorded.
• Customers (future patients): Delays in addressing the FDA clinical hold mean that the pancreatic cancer treatment remains unavailable, impacting potential beneficiaries.
• Creditors: The company's liquidity position, while projected to be sufficient for 12 months, is dependent on future capital raises for clinical trials, which could affect its ability to meet long-term obligations.
• Regulatory Authorities (FDA): The company is actively engaged in addressing the FDA's clinical hold requirements, indicating a commitment to regulatory compliance, albeit with ongoing challenges.

Next Steps

• Continue active dialogue with the FDA to seek permission to forego the large animal study and address remaining clinical hold requirements.
• Provide additional data to the FDA to lift the clinical hold.
• Prepare for next steps and add requested information to the drug master file in ongoing dialogue with SG Austria.
• Complete the review by the Business Review Committee and the Board to determine actions and plans for development programs and the relationship with SG Austria.
• Seek stockholder approval by October 31, 2025, for the issuance of Series C Preferred Shares exceeding 19.99% of outstanding common stock, as required by Nasdaq listing standards.
• File a resale registration statement for the Series C conversion shares and warrant shares by September 16, 2025.
• TNF Pharmaceuticals, Inc. to seek stockholder approval by November 16, 2025, for the issuance of Series H Preferred Shares exceeding 19.99% of TNF common stock.
• Identify alternative approaches to expand the prodrug/activator technology for cancer treatment.
• Obtain additional capital to complete a clinical trial for pancreatic cancer.

Key Dates

Recommendation

The company faces significant challenges, including a substantial net loss, an ongoing FDA clinical hold on its primary drug candidate, and material weaknesses in internal controls. While a recent capital raise provides short-term liquidity and some progress has been made on FDA requests, the strategic review and reliance on a potentially misaligned related party (SG Austria) introduce considerable uncertainty. The stock is a 'hold' for investors who are already invested and willing to wait for clarity on the clinical hold resolution and the outcome of the strategic review, but new investors should exercise extreme caution given the high risks and lack of clear positive catalysts in the near term.

Keywords

Biotechnology, Cellular Therapy, Cancer Treatment, Pancreatic Cancer, LAPC, CypCaps, Cell-in-a-Box, FDA Clinical Hold, IND Application, SEC Filing, 10-Q, Financial Results, Biopharma, Clinical Trials, Drug Development, Capital Raise, Warrants, Preferred Stock, TNF Pharmaceuticals, Femasys